TERZAH HORTON

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    R01CA193776     (TEACHEY, DAVID T.)May 4, 2015 - Jan 31, 2028
    NIH
    Improving risk allocation and developing novel therapies for children with T-ALL and T-LL
    Role Description: RENEWAL start date 12/1/2022 end date 11/30/2027
    Role: co-principle investigator

    R01CA164024     (HORTON, TERZAH M)Feb 5, 2013 - Jan 31, 2019
    NIH
    Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
    Role: Principal Investigator

    K23CA113775     (HORTON, TERZAH M)Jun 1, 2006 - May 31, 2011
    NIH
    Proteosome Inhibition Therapy for Hematologic Malignancy
    Role: Principal Investigator

    F32CA009329     (HORTON, TERZAH M)Jan 25, 1993
    NIH
    MITOCHONDRIAL DNA MUTATIONS IN CARCINOGENESIS
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas S, Winter SS, Wood C, Zweider-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE, Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 May 16; 143(20):2053-2058. PMID: 38457359; PMCID: PMC11143515.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Horton TM, Kornblau SM. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers (Basel). 2024 Apr 09; 16(8). PMID: 38672531; PMCID: PMC11048007.
      Citations:    
    3. Lyu A, Humphrey RS, Nam SH, Durham TA, Hu Z, Arasappan D, Horton TM, Ehrlich LIR. Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia. Nat Commun. 2023 10 07; 14(1):6270. PMID: 37805579; PMCID: PMC10560206.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Tarlock K, Liu X, Minard CG, Isikwei EA, Reid JM, Horton TM, Fox E, Weigel BJ, Cooper T. Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672. PMID: 37710306; PMCID: PMC10864008.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    5. Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, Horton TM, Kornblau SM. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109. PMID: 37287368; PMCID: PMC10700663.
      Citations:    Fields:    Translation:HumansCells
    6. Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KW, Uppal M, He F, Zhang W, Gao Q, Yellapantula VD, Trujillo-Alonso V, Park SI, Oberley MJ, Ruckdeschel E, Lim MS, Wertheim GB, Barth MJ, Horton TM, Derkach A, Kovach AE, Forlenza CJ, Zhang Y, Landgren O, Moskowitz CH, Cesarman E, Imielinski M, Elemento O, Roshal M, Giulino-Roth L. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells. Blood Cancer Discov. 2023 05 01; 4(3):208-227. PMID: 36723991; PMCID: PMC10150291.
      Citations: 2     Fields:    Translation:HumansCells
    7. Hubner SE, de Camargo Magalh?es ES, Hoff FW, Brown BD, Qiu Y, Horton TM, Kornblau SM. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023 Mar 20; 24(6). PMID: 36982970; PMCID: PMC10058043.
      Citations:    Fields:    Translation:HumansCells
    8. Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci. 2023 Mar 13; 24(6). PMID: 36982537; PMCID: PMC10056740.
      Citations:    Fields:    Translation:Humans
    9. Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660. PMID: 36322844; PMCID: PMC9945772.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    10. Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, Kornblau SM. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343. PMID: 35021602; PMCID: PMC9521248.
      Citations: 2     Fields:    
    11. Teachey , DT Devidas M Wood BL Chen Z HORTON TM Jaju AI, Messinger YH Loh ML Hunger SP Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology. 2022; 40(19):2106-2118.
    12. Stevens AM, Horton TM, Glasser CL, Gerbing RB, Aplenc R, Alonzo TA, Redell MS. IL-10 and TNFa are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatr Hematol Oncol. 2023 Mar; 40(2):147-158. PMID: 35838057; PMCID: PMC10498011.
      Citations:    Fields:    
    13. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Konopleva M, Tremblay M, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Sauvageau G, Hoang T. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022 05 19; 13(1):2801. PMID: 35589701; PMCID: PMC9120040.
      Citations:    Fields:    Translation:AnimalsCells
    14. Meyer LK, Delgado-Martin C, Sharp PP, Huang BJ, McMinn D, Vincent TL, Ryan T, Horton TM, Wood BL, Teachey DT, Taunton J, Kirk CJ, Hermiston ML. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 07; 198(1):137-141. PMID: 35434798; PMCID: PMC9322670.
      Citations:    Fields:    Translation:HumansCells
    15. Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118. PMID: 35271306; PMCID: PMC9242409.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    16. Johnston RL, Mottok A, Chan FC, Jiang A, Diepstra A, Visser L, Gascoyne RD, Friedman DL, Schwartz CL, Kelly KM, Scott DW, Horton TM, Steidl C, Telenius A. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022 02 10; 139(6):889-893. PMID: 34662378; PMCID: PMC8832480.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    17. Baran N Lodi A Dhungana Y herbrich S HORTON TM KornblauS Rezvani K Sauvageau G Gagea M Andreeff M Takahashi K Marszalek JR Lorenzi PL, Yu J TizianaS HoangT Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell lymphoblastic leukemia. Nature Communications. 2022; 13(1):2801.
    18. Hoff FW, Horton TM, Kornblau SM. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Rev Proteomics. 2021 12; 18(12):1087-1097. PMID: 34965151; PMCID: PMC9148717.
      Citations:    Fields:    Translation:HumansCells
    19. Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 12 14; 5(23):4864-4876. PMID: 34543389; PMCID: PMC9153032.
      Citations: 1     Fields:    Translation:HumansAnimals
    20. van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072. PMID: 34719869; PMCID: PMC9041833.
      Citations:    Fields:    Translation:HumansCells
    21. Abdelhamed S, Butler JT, Jung S, Chen DW, Jenkins G, Gao L, Lim JY, Klco JM, Horton TM, Kurre P. Rational biomarker development for the early and minimally invasive monitoring of AML. Blood Adv. 2021 11 09; 5(21):4515-4520. PMID: 34587228; PMCID: PMC8579272.
      Citations:    Fields:    Translation:HumansAnimals
    22. Schraw JM, Woodhouse JP, Bernhardt MB, Taylor OA, Horton TM, Scheurer ME, Okcu MF, Rabin KR, Lupo PJ, Brown AL. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613. PMID: 34608220; PMCID: PMC8490393.
      Citations:    Fields:    Translation:Humans
    23. Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12). PMID: 34207315; PMCID: PMC8234433.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    24. Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060. PMID: 32959058; PMCID: PMC7907722.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    25. Agrusa JE, Scull BP, Abhyankar HA, Lin H, Ozuah NW, Chakraborty R, Eckstein OS, Gulati N, Fattah EA, El-Mallawany NK, Rouce RH, Dreyer ZE, Brackett J, Margolin JF, Lubega J, Horton TM, Bollard CM, Gramatges MM, Kamdar KY, McClain KL, Man TK, Allen CE. Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers (Basel). 2020 Dec 02; 12(12). PMID: 33276546; PMCID: PMC7761312.
      Citations: 1     
    26. Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 02 20; 233:104046. PMID: 33212251; PMCID: PMC7877245.
      Citations: 1     Fields:    Translation:Humans
    27. Lyu A, Triplett TA, Nam SH, Hu Z, Arasappan D, Godfrey WH, Ames RY, Sarang A, Selden HJ, Lee CH, Georgiou G, Horton TM, Ehrlich LIR. Tumor-associated myeloid cells provide critical support for T-ALL. Blood. 2020 10 15; 136(16):1837-1850. PMID: 32845007.
      Citations: 6     Fields:    Translation:HumansCells
    28. Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020 Jun 23; 11(25):2387-2403. PMID: 32637030; PMCID: PMC7321696.
      Citations: 2     Fields:    
    29. Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Nachmias B, MacLean N, Wang X, Arruda A, Minden MD, Horton TM, Kornblau SM, Chan SM, Bader GD, Raught B, Schimmer AD. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020 04 08; 12(538). PMID: 32269163.
      Citations: 17     Fields:    Translation:HumansCells
    30. Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, Kolb EA, Gamis A. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020 07; 105(7):1879-1886. PMID: 32029509; PMCID: PMC7327649.
      Citations: 34     Fields:    Translation:Humans
    31. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876. PMID: 31687977; PMCID: PMC6994137.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    32. Stevens AM, Xiang M, Heppler LN, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA, To?ic I. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227. PMID: 31856268; PMCID: PMC6929386.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    33. Wilmarth PA, Horton T, Kurre P, Abdelhamed S, Butler JT, Doron B, Halse A, Nemecek E, Marks DL, Chang BH. Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche. EMBO Rep. 2019 07; 20(7):e47546. PMID: 31267709; PMCID: PMC6607014.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    34. Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 07; 186(2):274-285. PMID: 30957229; PMCID: PMC6606340.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    35. Hashmi SK, Horton TM, Doron B, Abdelhamed S, Butler JT, Kurre P. Transmissible ER stress reconfigures the AML bone marrow compartment. Leukemia. 2019 04; 33(4):918-930. PMID: 30206307; PMCID: PMC6411460.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    36. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238. PMID: 30122620; PMCID: PMC6487196.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    37. Hoff FW, Hu CW, Qutub AA, de Bont ESJM, Horton TM, Kornblau SM. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics. 2018 07; 15(7):613-622. PMID: 29898608; PMCID: PMC6444923.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    38. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM, Kornblau SM. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286. PMID: 29669821; PMCID: PMC6512776.
      Citations: 7     Fields:    Translation:Humans
    39. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, de Bont ESJM, Qutub AA, Kornblau SM, Horton TM. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274. PMID: 29669823; PMCID: PMC6496939.
      Citations: 5     Fields:    Translation:Humans
    40. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999. PMID: 29305553; PMCID: PMC5833263.
      Citations: 48     Fields:    Translation:HumansAnimals
    41. Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):355-364. PMID: 29190164; PMCID: PMC6191173.
      Citations: 1     Fields:    Translation:Humans
    42. Esbenshade AJ, Pierson CR, Thompson AL, Reed D, Gupta A, Levy A, Kahalley LS, Harker-Murray P, Schore R, Muscal JA, Embry L, Maloney K, Horton T, Zweidler-Mckay P, Dhall G. Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3). PMID: 29193588; PMCID: PMC7773146.
      Citations: 2     Fields:    Translation:Humans
    43. Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343. PMID: 28642300; PMCID: PMC5685242.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    44. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017 12; 31(12):2568-2576. PMID: 28484265; PMCID: PMC5729333.
      Citations:    
    45. Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 09; 57(9):1183-1193. PMID: 28419486; PMCID: PMC5561493.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    46. Gramatges MM, Deshpande A, Lupo PJ, Rau RE, Redell ML, Horton TM, Scheurer ME, Rabin KR. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9). PMID: 28266784.
      Citations: 5     Fields:    Translation:Humans
    47. Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Zweegman S, Jansen G, Cloos J, Musters RJ. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget. 2016 Nov 15; 7(46):74779-74796. PMID: 27542283; PMCID: PMC5342701.
      Citations: 10     Fields:    Translation:HumansCells
    48. Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016 09 06; 9(1):82. PMID: 27599459; PMCID: PMC5011854.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    49. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43. PMID: 26884558; PMCID: PMC4872308.
      Citations: 24     Fields:    Translation:Humans
    50. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74. PMID: 26727639; PMCID: PMC4899280.
      Citations: 5     Fields:    Translation:Humans
    51. Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL, L?pez-Terrada D. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22. PMID: 25833390; PMCID: PMC4478135.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    52. Horton T. Yin and yang of glucocorticoid receptors in apoptosis. Blood. 2015 Jan 08; 125(2):209-11. PMID: 25573965.
      Citations: 1     Fields:    Translation:HumansAnimals
    53. Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Schuurhuis GJ, Moscow JA, Kelder A. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60. PMID: 24976003; PMCID: PMC4247259.
      Citations: 24     Fields:    Translation:HumansAnimalsCTClinical Trials
    54. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9. PMID: 24771494; PMCID: PMC4126862.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    55. Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013 Dec; 98(12):1896-904. PMID: 24056819; PMCID: PMC3856965.
      Citations: 29     Fields:    Translation:Humans
    56. Levy AS, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM. Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol. 2013 Aug; 35(6):456-61. PMID: 23892351; PMCID: PMC3839621.
      Citations: 11     Fields:    Translation:Humans
    57. Horton T, Hunger SP. Children are not large mice. Eur J Haematol. 2013 Jun; 90(6):535. PMID: 23534840.
      Citations:    Fields:    Translation:HumansAnimalsCells
    58. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7. PMID: 23554030; PMCID: PMC4139006.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    59. Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T, Keller FG, COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013 Jun; 60(6):972-8. PMID: 23255501.
      Citations: 18     Fields:    Translation:Humans
    60. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5. PMID: 22887890; PMCID: PMC3511610.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    61. Horton TM, Sheehan AM, Hutchison RE, Narendra S, Wu MF, Liu H, L?pez-Terrada D. Analysis of NF-?B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study. Lymphoma. 2012; 2012. PMID: 31406604; PMCID: PMC6690044.
      Citations:    
    62. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573; PMCID: PMC3218253.
      Citations: 33     Fields:    Translation:HumansCells
    63. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012 Feb; 26(2):271-9. PMID: 21844871; PMCID: PMC3833621.
      Citations:    
    64. Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9. PMID: 21190039.
      Citations: 2     Fields:    Translation:Humans
    65. Margolin J, Horton T, Venkateswaran L, Lee D, Yee DL, Mahoney D, Frug? E. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4. PMID: 20589622.
      Citations: 1     Fields:    Translation:Humans
    66. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA, ALLNA 2008 Conference. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. PMID: 20127846; PMCID: PMC2857540.
      Citations: 7     Fields:    Translation:Humans
    67. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42. PMID: 19671751; PMCID: PMC3741063.
      Citations: 35     Fields:    Translation:HumansCells
    68. Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul; 50(7):1174-82. PMID: 19557638.
      Citations: 3     Fields:    Translation:HumansCells
    69. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25. PMID: 19526240; PMCID: PMC2953793.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    70. Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D. Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem. 2009 Sep 15; 392(2):133-8. PMID: 19497291; PMCID: PMC2713383.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    71. Thompson PA, Allen CE, Horton T, Jones JY, Vinks AA, McClain KL. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5. PMID: 19137570; PMCID: PMC3660724.
      Citations: 11     Fields:    Translation:Humans
    72. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL, Children's Oncology Group. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92. PMID: 17668866; PMCID: PMC6777707.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    73. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM, Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8. PMID: 17971589; PMCID: PMC6684202.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    74. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22. PMID: 17332297.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    75. Min DJ, Moskowitz NP, Brownstein C, Lee H, Horton TM, Carroll WL. Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis. 2006 Nov; 11(11):1977-86. PMID: 17013760.
      Citations: 4     Fields:    Translation:HumansCells
    76. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
      Citations: 41     Fields:    Translation:HumansCells
    77. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9. PMID: 15756014.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    78. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9. PMID: 15570082.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    79. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004 Nov; 145(5):617-21. PMID: 15520760.
      Citations: 6     Fields:    Translation:Humans
    80. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9. PMID: 12679653.
      Citations: 3     Fields:    Translation:Humans
    81. Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD, Gramlich T, Wallace DC. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer. 1996 Feb; 15(2):95-101. PMID: 8834172.
      Citations: 43     Fields:    Translation:HumansCells
    82. Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace DC. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995 Oct; 45(10):1879-83. PMID: 7477986.
      Citations: 36     Fields:    Translation:HumansCells
    83. Wallace DC, Shoffner JM, Trounce I, Brown MD, Ballinger SW, Corral-Debrinski M, Horton T, Jun AS, Lott MT. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995 May 24; 1271(1):141-51. PMID: 7599200.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    84. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 1994 Sep 15; 23(2):471-6. PMID: 7835898.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    85. Ranheim TS, Shisler J, Horton TM, Wold LJ, Gooding LR, Wold WS. Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol. 1993 Apr; 67(4):2159-67. PMID: 8445725; PMCID: PMC240323.
      Citations: 18     Fields:    Translation:AnimalsCells
    86. Gooding LR, Aquino L, Duerksen-Hughes PJ, Day D, Horton TM, Yei SP, Wold WS. The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol. 1991 Jun; 65(6):3083-94. PMID: 1827845; PMCID: PMC240964.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    87. Horton TM, Tollefson AE, Wold WS, Gooding LR. A protein serologically and functionally related to the group C E3 14,700-kilodalton protein is found in multiple adenovirus serotypes. J Virol. 1990 Mar; 64(3):1250-5. PMID: 2304142; PMCID: PMC249240.
      Citations: 16     Fields:    Translation:AnimalsCells
    HORTON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (392)
    Explore
    _
    Co-Authors (64)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _